[go: up one dir, main page]

AU2001290312A1 - Peg-modified erythropoietin - Google Patents

Peg-modified erythropoietin

Info

Publication number
AU2001290312A1
AU2001290312A1 AU2001290312A AU9031201A AU2001290312A1 AU 2001290312 A1 AU2001290312 A1 AU 2001290312A1 AU 2001290312 A AU2001290312 A AU 2001290312A AU 9031201 A AU9031201 A AU 9031201A AU 2001290312 A1 AU2001290312 A1 AU 2001290312A1
Authority
AU
Australia
Prior art keywords
peg
epo
conjugated
native
erythropoietin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001290312A
Inventor
Hiromitsu Kawata
Minoru Machida
Hajime Miyamoto
Teruo Nakamura
Yasuo Sekimori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of AU2001290312A1 publication Critical patent/AU2001290312A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides a polyethylene glycol-conjugated erythropoietin (PEG-conjugated EPO) prepared by PEG conjugation on the lysine residue at position 52 of native erythropoietin (native EPO). In order to achieve more sustained efficacy without losing physiological activities of native EPO, a glycoprotein rich in sugar chains, there has been a need to develop a PEG-conjugated EPO with significantly sustained efficacy by introducing a controlled number of PEG molecules at controlled positions. This PEG-conjugated EPO addresses such a need and provides more sustained efficacy.
AU2001290312A 2000-10-16 2001-09-28 Peg-modified erythropoietin Abandoned AU2001290312A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-315421 2000-10-16
JP2000315421 2000-10-16
PCT/JP2001/008539 WO2002032957A1 (en) 2000-10-16 2001-09-28 Peg-modified erythropoietin

Publications (1)

Publication Number Publication Date
AU2001290312A1 true AU2001290312A1 (en) 2002-04-29

Family

ID=18794529

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001290312A Abandoned AU2001290312A1 (en) 2000-10-16 2001-09-28 Peg-modified erythropoietin

Country Status (8)

Country Link
US (2) US20040082765A1 (en)
EP (1) EP1333036B1 (en)
JP (1) JP5170931B2 (en)
AT (1) ATE421535T1 (en)
AU (1) AU2001290312A1 (en)
DE (1) DE60137525D1 (en)
ES (1) ES2320101T3 (en)
WO (1) WO2002032957A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2511814C (en) * 2002-12-26 2015-02-17 Mountain View Pharmaceuticals, Inc. Polymer conjugates of interferon-beta with enhanced biological potency
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7314859B2 (en) 2002-12-27 2008-01-01 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
CA2458085A1 (en) 2003-03-21 2004-09-21 F. Hoffmann-La Roche Ag Transcriptional activity assay
EP1471153A3 (en) * 2003-03-21 2005-06-15 F. Hoffmann-La Roche Ag Transcriptional activity assay
JP2007537986A (en) * 2003-05-30 2007-12-27 セントカー・インコーポレーテツド Formation of a novel erythropoietin complex using transglutaminase
KR20060123472A (en) * 2003-12-10 2006-12-01 넥타르 테라퓨틱스 에이엘, 코포레이션 Compositions Comprising Two Different Groups of Polymer-Active Conjugates
JP4903580B2 (en) * 2003-12-30 2012-03-28 アウグスティヌス・バーダー Tissue regeneration law
US7714114B2 (en) 2005-02-16 2010-05-11 Nektar Therapeutics Conjugates of an EPO moiety and a polymer
EP1893240A2 (en) * 2005-06-13 2008-03-05 Nastech Pharmaceutical Company Inc. Transmucosal delivery of peptide derivatives
IL169377A (en) 2005-06-23 2012-09-24 Avigdor Shafferman Uniformly conjugated serine hydrolases
EP2380435B1 (en) 2005-08-31 2016-05-25 Kaneka Corporation Feline-derived erythropoietin and method for production thereof
US20080171696A1 (en) * 2005-10-21 2008-07-17 Avigenics, Inc. Pharmacodynamically enhanced therapeutic proteins
CU23556A1 (en) 2005-11-30 2010-07-20 Ct Ingenieria Genetica Biotech POLYMER STRUCTURE SIMILAR TO DENDRÍMERO FOR THE OBTAINING OF CONJUGATES OF PHARMACEUTICAL INTEREST
US7985839B2 (en) 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
US7982010B2 (en) 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
MX2008012600A (en) 2006-03-31 2008-12-12 Baxter Int Pegylated factor viii.
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
JP5419689B2 (en) 2006-07-25 2014-02-19 リポクセン テクノロジーズ リミテッド Derivatization of granulocyte colony-stimulating factor
GB0615067D0 (en) * 2006-07-28 2006-09-06 Ttp Communications Ltd Reconfigurable signal processing scheme
KR101304081B1 (en) * 2006-08-04 2013-09-05 프로롱 파마슈티컬스, 엘엘씨 Modified erythropoietin
ES2655639T3 (en) 2006-12-15 2018-02-21 Baxalta GmbH Conjugate of factor VIIa - (poly) sialic acid that has a prolonged half-life in vivo
US8110651B2 (en) 2008-01-11 2012-02-07 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
US8101706B2 (en) * 2008-01-11 2012-01-24 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
GB0922354D0 (en) 2009-12-21 2010-02-03 Polytherics Ltd Novel polymer conjugates
US8198242B2 (en) 2009-05-20 2012-06-12 Biomarin Pharmaceutical Inc. Variants of C-type natriuretic peptide
SG10201602211PA (en) * 2009-09-15 2016-04-28 Kaneka Corp Modified Erythropoietin To Which Water-Soluble Long-Chain Molecule Is Added
US10188739B2 (en) 2014-02-27 2019-01-29 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5100664A (en) * 1985-09-20 1992-03-31 Cetus Corporation Human IL-2 as a vaccine adjuvant
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
JP2502646B2 (en) 1988-01-19 1996-05-29 松下電器産業株式会社 Burner
JPH029900A (en) * 1988-04-12 1990-01-12 Kirin Amgen Inc Modified erythropoetine
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
NO934477L (en) * 1992-12-09 1994-06-10 Ortho Pharma Corp PEG hydrazone and PEG oxime-binding reagents and protein derivatives thereof
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5747446A (en) * 1994-03-22 1998-05-05 Beth Israel Deaconess Medical Center Modified polypeptides with increased biological activity
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP4067058B2 (en) * 1995-03-10 2008-03-26 中村 敏一 PEGylated HGF
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
ATE341344T1 (en) * 1996-08-02 2006-10-15 Ortho Mcneil Pharm Inc POLYPEPTIDES WITH SINGLE COVALENTLY BONDED N-TERMINAL WATER SOLUBLE POLYMER
ATE200030T1 (en) * 1997-01-29 2001-04-15 Polymasc Pharmaceuticals Plc PEGYLATION PROCEDURE
WO2000042175A1 (en) * 1999-01-14 2000-07-20 Bolder Biotechnology Inc. Methods for making proteins containing free cysteine residues
IL133974A0 (en) * 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
JP2002531089A (en) * 1998-11-30 2002-09-24 イーライ・リリー・アンド・カンパニー Erythropoietic compounds
CZ300546B6 (en) 1999-01-29 2009-06-10 Amgen, Inc. Physiologically active conjugate, composition and process for preparing thereof
CZ299516B6 (en) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Erythropoietin glycoprotein conjugate, process for its preparation and use and pharmaceutical composition containing thereof
PE20010288A1 (en) * 1999-07-02 2001-03-07 Hoffmann La Roche ERYTHROPOYETIN DERIVATIVES

Also Published As

Publication number Publication date
JPWO2002032957A1 (en) 2004-02-26
EP1333036A1 (en) 2003-08-06
ES2320101T3 (en) 2009-05-19
ATE421535T1 (en) 2009-02-15
US20060276634A1 (en) 2006-12-07
DE60137525D1 (en) 2009-03-12
WO2002032957A1 (en) 2002-04-25
EP1333036B1 (en) 2009-01-21
US20040082765A1 (en) 2004-04-29
US8022191B2 (en) 2011-09-20
JP5170931B2 (en) 2013-03-27
EP1333036A4 (en) 2004-09-29

Similar Documents

Publication Publication Date Title
AU2001290312A1 (en) Peg-modified erythropoietin
WO2003055526A3 (en) Erythropoietin conjugates
AU2001296962A1 (en) Pegylated interleukin-10
IL206445A0 (en) Peptide conjugate of exendin-4(1-39)variant in combination with an antidiabetic agent for use in the treatment of type 2 diabetes mellitus
WO2000021574A3 (en) Site-directed dual pegylation of proteins
EP1454138A4 (en) Immunocytokines with modulated selectivity
DE3786000D1 (en) CONJUGATE POETS STAR.
WO2006081249A3 (en) Conjugates of biologically active proteins having a modified in vivo half-life
WO1999004820A3 (en) Cytolysis of target cells by superantigen conjugates inducing t-cell activation
PT1264840E (en) Long lasting fusion peptide inhibitors of viral infection
ATE550041T1 (en) TRANSGLUTAMINASE-MEDIATED CONJUGATION OF PEPTIDES
WO2000012587A3 (en) Polyamide chains of precise length, methods to manufacture them and their conjugates
YU54301A (en) Gcsf conjugates
IL193365A0 (en) Aggregate-free urate oxidases, polymer conjugates thereof and compositions prepared therefrom
CA2286098A1 (en) Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods
HK1049283A1 (en) Amphiphilic polymers and polypeptide conjugates comprising same
HK1042287A1 (en) Valency platform molecules comprising aminooxy groups
AU4660789A (en) Polypeptide derivatives
DK0557199T3 (en) Polyethylene Glycol-Hirudin Conjugates
CA2373252A1 (en) Long lasting anti-angiogenic peptides
TR200200599T2 (en) Human insulin monomeric analogues.
WO2023154564A3 (en) Cd206 targeted peptide conjugates and methods of using the same
EP1095652A3 (en) Melanins with improved ability to inhibit HIV replication
ATE313796T1 (en) CONJUGATES OF DEFINED STOICHIOMETRY
WO2004014951A3 (en) Binding molecules